Page last updated: 2024-09-05

sb 203580 and sanguinarine

sb 203580 has been researched along with sanguinarine in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(sanguinarine)
Trials
(sanguinarine)
Recent Studies (post-2010) (sanguinarine)
3,48941,13767537290

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)sanguinarine (IC50)
CholinesteraseHomo sapiens (human)7.08
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)2
AcetylcholinesteraseHomo sapiens (human)1.22
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)2
Transcription factor p65Homo sapiens (human)2

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aburai, N; Kimura, K; Ohnishi, M; Yoshida, M1

Other Studies

1 other study(ies) available for sb 203580 and sanguinarine

ArticleYear
Sanguinarine as a potent and specific inhibitor of protein phosphatase 2C in vitro and induces apoptosis via phosphorylation of p38 in HL60 cells.
    Bioscience, biotechnology, and biochemistry, 2010, Volume: 74, Issue:3

    Topics: Apoptosis; Benzophenanthridines; Caspase 3; Caspase 7; Enzyme Inhibitors; HL-60 Cells; Humans; Imidazoles; Isoquinolines; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 2C; Pyridines

2010